Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Young Kyung | - |
dc.contributor.author | Kim, Jeong Yeon | - |
dc.contributor.author | Park, Dae Won | - |
dc.contributor.author | Sohn, Jang Wook | - |
dc.contributor.author | Kim, Min Ja | - |
dc.date.accessioned | 2021-09-08T03:20:34Z | - |
dc.date.available | 2021-09-08T03:20:34Z | - |
dc.date.created | 2021-06-11 | - |
dc.date.issued | 2010-05 | - |
dc.identifier.issn | 0305-7453 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/116483 | - |
dc.description.abstract | The high prevalence of methicillin-resistant Staphylococcus aureus (MRSA) coupled with an increase in vancomycin use have induced vancomycin tolerance in MRSA, adversely affecting the outcome of MRSA bacteraemia. This study aimed to identify predictors of persistent MRSA bacteraemia (PMRSAB) in patients treated with vancomycin. A retrospective, case-control study was performed at a university hospital in Korea from January 2006 to February 2009. Subjects included 96 patients who had MRSA bacteraemia and received vancomycin under therapeutic drug monitoring. We compared the clinical characteristics, management and outcomes of cases with PMRSAB (>= 7 days, n = 31) with controls with non-PMRSAB (< 3 days, n = 32). Vancomycin MICs were determined by the Vitek 2 system. Of 96 patients with MRSA bacteraemia, MRSA isolates from 21 patients (21.9%) showed a vancomycin MIC of 2 mg/L. Independent predictors of PMRSAB were: retention of implicated medical devices [odds ratio (OR), 10.35; 95% confidence interval (CI), 1.03-104.55]; MRSA infection of at least two sites (OR, 10.24; 95% CI, 1.72-61.01); and vancomycin MIC of 2 mg/L (OR, 6.34; 95% CI, 1.21-33.09). The frequency of side effects and mean trough serum vancomycin concentrations were not significantly different between the two groups. Sixteen patients with PMRSAB subsequently received teicoplanin +/- arbekacin, linezolid or quinupristin/dalfopristin, due to vancomycin failure or intolerance. To minimize the risk of PMRSAB, early removal of implicated devices and evaluation for metastatic infections should be encouraged. Alternative antibiotic therapy is warranted for infections due to isolates with elevated vancomycin MICs, as well as for the high rates of side effects. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | OXFORD UNIV PRESS | - |
dc.title | Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoon, Young Kyung | - |
dc.contributor.affiliatedAuthor | Park, Dae Won | - |
dc.contributor.affiliatedAuthor | Sohn, Jang Wook | - |
dc.contributor.affiliatedAuthor | Kim, Min Ja | - |
dc.identifier.doi | 10.1093/jac/dkq050 | - |
dc.identifier.scopusid | 2-s2.0-77953703747 | - |
dc.identifier.wosid | 000276527500030 | - |
dc.identifier.bibliographicCitation | JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, v.65, no.5, pp.1015 - 1018 | - |
dc.relation.isPartOf | JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | - |
dc.citation.title | JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | - |
dc.citation.volume | 65 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1015 | - |
dc.citation.endPage | 1018 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Microbiology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Microbiology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordAuthor | risk factors | - |
dc.subject.keywordAuthor | minimum inhibitory concentration | - |
dc.subject.keywordAuthor | case-control study | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.